← Deep analysesHome
mttssn research · Nordic Deep Dive
Cantargia (CANTA.ST)
Hälsovård · Svenskt kliniskt biotech (pre-kommersiellt) · LTM Q1 2026
Analysis date: 2026-07-21
Price at analysis: SEK 1.94
Method: mttssn_manual_v1
Conviction: LOW
HOLD
Conviction: LOW
Cantargia is a pre-commercial clinical-stage biotech: recurring economics are a loss by design (adjusted NOPAT −SEK 154m, ROIC −66%, EP −SEK 173m), so ROIC/EP are not the value gauge. The enterprise is off the balance sheet — lead asset CAN04/nadunolimab (Phase 2, FDA Fast Track) plus a retained royalty and up to USD 580–613m of milestones on Otsuka's CAN10. Cash runway ~2–2.5 years. Pure binary optionality — speculative HOLD, low conviction.
Adj. ROIC
-66.0%
WACC 8% → spread -74.0pp
Economic Profit
SEK -173M
−SEK 173m by design; not the value gauge (off-BS pipeline)
FCF Yield
n/a
Burn ~SEK 26m/quarter; ~2–2.5-yr runway on SEK 258m
Price / Target
SEK 1.94 → SEK 2.10
+8% base; HOLD
Revenue (LTM)
SEK 317M
LTM Q1'26 recurring ≈ nil (FY revenue was one-off CAN10)
EBIT Margin
n/a
NM — pre-commercial clinical stage
EV / IC
n/a
Enterprise value / invested capital
Net Debt
n/a
Net cash SEK 258m (EV SEK 225m)
Thesis

Cantargia is a single-asset clinical-stage biotech; the FY2025 reported operating profit was entirely a one-off — the SEK 317m CAN10 out-licence to Otsuka (flagged a Key Audit Matter). On a recurring basis it loses money by design: adjusted NOPAT −SEK 154m, ROIC −66%, EP −SEK 173m. Balance-sheet returns are not the value gauge here — the enterprise is the off-balance-sheet pipeline.

The value case is two-legged optionality: lead antibody CAN04/nadunolimab in Phase 2 (promising PDAC/TNBC survival signals, FDA Fast Track), plus the retained economics on Otsuka's global CAN10 — up to USD 580–613m in milestones and low-double-digit royalties. The Otsuka deal is genuine validation and a non-dilutive funding bridge.

The constraint is cash and binarity: ~SEK 258m of funds against ~SEK 26m/quarter recurring burn gives roughly a 2–2.5-year runway, so a dilutive raise or a milestone is needed before the next value inflection. Outcomes are binary — a quality/value mandate cannot underwrite this at size.

Valuation · reverse-DCF & scenarios

The standard reverse-DCF / economic-profit frame does not apply: ROIC and EP are negative by design and IC is essentially the cash war-chest. The market prices the pipeline at ~SEK 225m enterprise (market cap SEK 483m less SEK 258m net cash) — a risk-adjusted option on Phase 2 data and Otsuka milestones.

Base SEK 2.10 (roughly the current risk-adjusted option value); bull SEK 6.00 if CAN04 Phase 2 delivers and Otsuka's CAN10 triggers milestones; bear SEK 0.80 on a trial miss or a dilutive rescue raise. The wide spread reflects the binary payoff, not a modelled intrinsic value.

Reverse-DCF panel unavailable: non-positive nopat.

Scenario24m targetUpsideProb.Driver
BullSEK 6+209%20%CAN04 Phase 2 delivers + Otsuka CAN10 milestones trigger
BaseSEK 2+8%45%Current risk-adjusted pipeline option value
BearSEK 1-59%35%Trial miss or dilutive rescue raise
Prob-weightedSEK 2+25%100%Scenario-weighted expected value
Key drivers

1. CAN04/nadunolimab Phase 2

Positive PDAC/TNBC survival data with FDA Fast Track would re-rate the equity multiples of the current option value.

2. Retained Otsuka economics

Up to USD 580–613m milestones + low-double-digit royalties on CAN10 — a non-dilutive, big-pharma-validated upside stream.

3. Net cash cushion

~SEK 258m of funds (EV only SEK 225m) part-covers downside and buys ~2–2.5 years of runway.

4. Partnership optionality

A further out-licence of CAN04, on the CAN10 template, would fund development without heavy dilution.

5. Clean reporting

Auditor-verified IFRS 15 treatment of the one-off; no accounting red flags to discount the option.

Key risks
Conclusion

Cantargia is a pre-commercial biotech whose recurring economics are negative by design — ROIC/EP are not the value gauge. The case rests on off-balance-sheet optionality: CAN04 Phase 2 plus retained Otsuka CAN10 milestones/royalties, part-cushioned by ~SEK 258m net cash. Speculative HOLD, low conviction; base target SEK 2.10.

This does not clear the book's quality bar and should be sized as a small binary option, not a core holding. The next Phase 2 readout and any Otsuka milestone are the value-determining catalysts; a dilutive raise before them is the principal downside trigger.

Footnote evidence & sources

Every adjustment traces to the cited note/page in the source filing — click to open it there. Annual report / 10-K: 📄 open  ·  Latest interim: 📄 open

Adjustment / figureValueSourceWhy mttssn treats it this way
One-off Otsuka CAN10 revenue (removed in full)317FY IS p.38 (Net Sales 316,702) + Note 5/6 p.53 + Directors' Report p.29 + Auditor KAM p.63 📄 p.53FY2025 net sales 316,702 KSEK 'solely generated from the acquisition of the CAN10 program by Otsuka Pharmaceutical' (Note 5, verbatim). USD 33M upfront on divesting the CAN10 IL1RAP program; IFRS 15 point-in-time transfer ('control transferred, no remaining performance obligations', Note 2.10). 100% non-recurring — stripped in full to reveal the recurring loss. Encoded as other_one_off_addback = -316.7 (removing a non-recurring gain).
LTM reported operating result (before strip)162computed: FY op 154,100 + Q1'26 -36,891 - Q1'25 -45,032 📄 p.13LTM operating result 162,241 KSEK is a one-off artifact of the FY Otsuka gain; positive only because the 316.7M one-off sits inside the FY anchor.
Recurring LTM operating result / adjusted NOPAT-154computed: LTM op 162.2 - one-off 316.7; tax = 0 📄 p.13162.2M - 316.7M = -154.5M. This is the true recurring operating LOSS run-rate. Tax = 0 (unrecognised DTA, loss carryforwards) so adjusted NOPAT = recurring EBIT = -154.5M.
Q1 2026 operating result (recurring quarterly run-rate)-36.9Q1 IS Operating result -36,891, p.13 📄 p.13Recurring quarterly operating LOSS -36,891 KSEK (vs -45,032 in Q1 2025 — R&D eased post-CAN10 handover). The clean recurring run-rate absent any one-off.
Q1 2026 total equity (IC base)234Q1 BS Total equity 233,951, p.14 📄 p.14Q1 2026 total equity 233,951 KSEK used as adjusted IC. No interest-bearing debt (25M loan repaid, 50M facility undrawn), no lease liabilities, no NCI, no OCI. IC = equity.
Q1 2026 cash + short-term investments (treated as operational)258Q1 BS p.14 (cash 246,034 + ST investments 12,000); Key Figures p.17 (Total available funds 258,034) 📄 p.17246,034 cash + 12,000 fixed-income fund investments = 258,034 KSEK total available funds. CLINICAL-STAGE OVERRIDE: treated as fully operational (R&D runway), excess_cash forced to 0, so IC stays positive at ~equity and ROIC is legitimately negative rather than a false positive.
Q1 2026 recurring operating cash burn (runway basis)-25.9Q1 Cash flow, 'Cash flow from operating activities' -25,909, p.16 📄 p.16Recurring operating cash burn -25,909 KSEK/quarter is the honest runway metric. Total change in cash -37,956 includes a one-time -12,000 reclassification into fixed-income funds (still available). On ~26M/q operating burn, 258M funds give ~2-2.5 yr runway absent financing/milestones — going-concern context.
Quality · Buffett tenets5 / 15
Understandable business
Clinical-stage Swedish biotech — a single lead antibody (CAN04/nadunolimab, Phase 2) plus a retained royalty on a partnered asset. No product revenue, binary trial outcomes; the enterprise value is entirely off the balance sheet and cannot be modelled from history.
Durable moat
[immateriella(patent/IP) · emerging] IL1RAP-antibody IP and FDA Fast Track give an emerging moat, validated by Otsuka paying USD 33m upfront for the CAN10 program. Test: no commercial franchise yet — the return spread is deeply negative (ROIC −66%) by design. Falsifier: Phase 2 readout failure or an IP challenge. Tagged emerging — never scored on promise alone.
Able & honest management
[allokering · candor] the CAN10 out-licence to Otsuka (USD 33m upfront, up to USD 580–613m milestones + low-double-digit royalties, upside retained) is shrewd non-dilutive capital allocation; reporting is clean (auditor KAM on the IFRS 15 one-off, verified). Röd flagga: a dilutive equity raise inside the ~2–2.5-year cash runway.
Financial strength
Pre-revenue: adjusted NOPAT −SEK 154m, ROIC −66%, EP −SEK 173m, cash burn ~SEK 26m/quarter against SEK 258m of funds — a ~2–2.5-year runway absent financing or milestones. On the returns dimension this is a red flag by design, not durable strength.
Margin of safety
The market values the pipeline at ~SEK 225m enterprise (EV, net of SEK 258m cash). Pure optionality on Phase 2 data and Otsuka milestones — no conservative intrinsic-value floor; the reverse-DCF/EP frame does not apply.